XERESE Drug Patent Profile
✉ Email this page to a colleague
When do Xerese patents expire, and what generic alternatives are available?
Xerese is a drug marketed by Bausch and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-five patent family members in twenty-one countries.
The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acyclovir; hydrocortisone profile page.
DrugPatentWatch® Generic Entry Outlook for Xerese
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 13, 2022. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for XERESE
International Patents: | 25 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for XERESE |
What excipients (inactive ingredients) are in XERESE? | XERESE excipients list |
DailyMed Link: | XERESE at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for XERESE
Generic Entry Date for XERESE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for XERESE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Meda Pharmaceuticals | Phase 3 |
TKL Research, Inc. | Phase 3 |
Pharmacology for XERESE
Anatomical Therapeutic Chemical (ATC) Classes for XERESE
US Patents and Regulatory Information for XERESE
XERESE is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of XERESE is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting XERESE
Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XERESE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | See Plans and Pricing | See Plans and Pricing |
Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XERESE
See the table below for patents covering XERESE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Algeria | 1966 | Combinaison pharmaceutique nouvelle. | See Plans and Pricing |
Turkey | 9801439 | See Plans and Pricing | |
Japan | 4260220 | See Plans and Pricing | |
Morocco | 23800 | See Plans and Pricing | |
China | 1131034 | See Plans and Pricing | |
Yugoslavia | 7296 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XERESE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0809498 | SPC/GB10/012 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
0809498 | 10C0038 | France | See Plans and Pricing | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
0809498 | CA 2010 00009 | Denmark | See Plans and Pricing | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |